Skip to main content

Advertisement

SpringerLink
Log in

Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Purpose

Careful patient selection plays a crucial role in avoiding overtreatment and further increases survival rates in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer (CRC) with peritoneal metastases (PM).

Methods

The clinical and molecular factors influencing survival in patients who had undergone CRS with HIPEC between January 2015 and December 2018 were analyzed.

Results

Sixty-six patients underwent CRS with HIPEC during the study period. The median overall survival (OS) was 36 months, with a 3-year OS of 43%. Multivariate analysis revealed increased PCI (HR: 1.21; 95% CI: 1.02–1.41; p = 0.020), right-sided primary tumor (HR: 3.01; 95% CI: 1.27–7.13; p = 0.017), and BRAF V600E mutation (HR: 4.55; 95% CI: 1.21–17.21; p = 0.025) as independent predictors for worse OS.

Conclusion

In addition to confirming the prognostic role of PCI, our study extends the role of BRAF mutation and right primary tumor location as markers for worse prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016;17:1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9.

    Article  PubMed  Google Scholar 

  2. Goéré D, Sourrouille I, Gelli M, Benhaim L, Faron M, Honoré C. Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives. Surg Oncol Clin N Am 2018;27:563–583. https://doi.org/10.1016/j.soc.2018.02.011.

  3. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263–7. https://doi.org/10.1200/JCO.2011.37.1039.

    Article  PubMed  Google Scholar 

  4. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study. J Clin Oncol 2004;22:3284–92. https://doi.org/10.1200/JCO.2004.10.012.

    Article  CAS  PubMed  Google Scholar 

  5. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681–5. https://doi.org/10.1200/JCO.2008.19.7160.

    Article  PubMed  Google Scholar 

  6. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer. J Clin Oncol 2003;21:3737–43. https://doi.org/10.1200/JCO.2003.04.187.

    Article  PubMed  Google Scholar 

  7. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, Kim TW, Ismail F, Tan IB, Yeh K-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol Off J Eur Soc Med Oncol 2018; 29:44–70. https://doi.org/10.1093/annonc/mdx738.

  8. Version 2.2020 (03 March 2020). Colon Cancer. Clinical Practice Guidelines in Oncology (NCCN Guidelines) n.d.

  9. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:256–66. https://doi.org/10.1016/S1470-2045(20)30599-4.

    Article  PubMed  Google Scholar 

  10. P H Sugarbaker, A M Averbach, P Jacquet, O A Stuart ADS. Hyperthermic Intraoperative Intreperitoneal Chemotherapy (HIIC) With Mitomycin C. Surg Technol Int 1996;5:245–9.

    CAS  PubMed  Google Scholar 

  11. Sugarbaker PH. Peritonectomy procedures. Perit Carcinomatosis A Multidiscip Approach 2007;221:247–64. https://doi.org/10.1007/978-0-387-48993-3_15.

    Article  Google Scholar 

  12. Rotolo S, Di Giorgio A, Santullo F, Attalla El Halabieh M, Lodoli C, Abatini C, et al. Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal metastases: analysis of short-term outcomes. Updates Surg 2021. https://doi.org/10.1007/s13304-021-01034-2.

  13. Segelman J, Granath F, Holm T, MacHado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699–705. https://doi.org/10.1002/bjs.8679.

    Article  CAS  PubMed  Google Scholar 

  14. Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications: Five-year experience. Ann Surg 2009;250:187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2.

    Article  PubMed  Google Scholar 

  15. Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: A systematic review and meta-analysis of current evidence. Oncotarget 2017;8:55657–83. https://doi.org/10.18632/oncotarget.17497.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Waite K, Youssef H. The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review. Ann Surg Oncol 2017;24:705–20. https://doi.org/10.1245/s10434-016-5712-3.

    Article  PubMed  Google Scholar 

  17. Elias D. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric french study. J Clin Oncol 2010;28:63–8. https://doi.org/10.1200/JCO.2009.23.9285.

    Article  PubMed  Google Scholar 

  18. Verwaal VJ, Van Ruth S, Witkamp A, Boot H, Van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65–71. https://doi.org/10.1007/s10434-004-1167-z.

    Article  PubMed  Google Scholar 

  19. Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. Ann Surg Oncol 2016;23:114–9. https://doi.org/10.1245/s10434-015-4627-8.

    Article  PubMed  Google Scholar 

  20. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol Suppl 1999;43:15–25. https://doi.org/10.1007/s002800051093.

    Article  Google Scholar 

  21. Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study. Ann Surg Oncol 2015;22:2958–64. https://doi.org/10.1245/s10434-015-4387-5.

    Article  PubMed  Google Scholar 

  22. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer a systematic review and meta-analysis. JAMA Oncol 2017;3:211–9. https://doi.org/10.1001/jamaoncol.2016.4227.

    Article  PubMed  Google Scholar 

  23. Nitsche U, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H, et al. Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Dig Surg 2016;33:157–63. https://doi.org/10.1159/000443644.

    Article  PubMed  Google Scholar 

  24. Price TJ, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer 2015;121:830–5. https://doi.org/10.1002/cncr.29129.

    Article  PubMed  Google Scholar 

  25. Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, et al. The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Ann Surg Oncol 2018;25:431–8. https://doi.org/10.1245/s10434-017-6264-x.

    Article  PubMed  Google Scholar 

  26. Dupré A, Malik HZ, Jones RP, Diaz-Nieto R, Fenwick SW, Poston GJ. Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases. Eur J Surg Oncol 2018;44:80–6. https://doi.org/10.1016/j.ejso.2017.10.218.

    Article  PubMed  Google Scholar 

  27. Kelly KJ, Alsayadnasser M, Vaida F, Veerapong J, Baumgartner JM, Patel S, et al. Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy? Ann Surg Oncol 2019;26:1421–7. https://doi.org/10.1245/s10434-019-07255-5.

    Article  PubMed  Google Scholar 

  28. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer 2017;84:69–80. https://doi.org/10.1016/j.ejca.2017.07.016.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: The “RASCAL II” study. Br J Cancer 2001;85:692–6. https://doi.org/10.1054/bjoc.2001.1964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/ RAS oncogenes and mismatch-repair status 2002;418:2002.

    Google Scholar 

  31. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466–74. https://doi.org/10.1200/JCO.2009.23.3452.

    Article  CAS  PubMed  Google Scholar 

  32. Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, et al. Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2014;25:2378–85. https://doi.org/10.1093/annonc/mdu464.

    Article  CAS  PubMed  Google Scholar 

  33. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VEPP, Rutten HJT, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396–402. https://doi.org/10.1093/annonc/mdq258.

    Article  PubMed  Google Scholar 

  34. Orlandi A, Calegari MA, Inno A, Berenato R, Caporale M, Niger M, et al. BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics 2015;16:2069–81. https://doi.org/10.2217/pgs.15.140.

    Article  CAS  PubMed  Google Scholar 

  35. Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives. Ann Oncol 2017;28:2648–57. https://doi.org/10.1093/annonc/mdx401.

    Article  CAS  PubMed  Google Scholar 

  36. Schneider MA, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T, et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 2018;268:845–53. https://doi.org/10.1097/SLA.0000000000002899.

    Article  PubMed  Google Scholar 

  37. Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A, et al. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. Ann Surg Oncol 2020;27:293–300. https://doi.org/10.1245/s10434-019-07452-2.

    Article  PubMed  Google Scholar 

  38. Guinney J, Dienstmann R, Wang X, De Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350–6. https://doi.org/10.1038/nm.3967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.Br J Surg 2018;105:e204–e211. https://doi.org/10.1002/bjs.10788.

  40. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: Integrating the consensus molecular subtypes. JNCCN J Natl Compr Cancer Netw 2017;15:411–9. https://doi.org/10.6004/jnccn.2017.0038.

    Article  Google Scholar 

  41. Cannon E, Buechler S. Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location. Clin Colorectal Cancer 2019;18:149–58. https://doi.org/10.1016/j.clcc.2019.02.002.

    Article  PubMed  Google Scholar 

  42. Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017;37:785–92. https://doi.org/10.3892/or.2016.5323.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy

    Andrea Di Giorgio, Francesco Santullo, Miriam Attalla El Halabieh, Claudio Lodoli, Carlo Abatini, Stefano Rotolo & Fabio Pacelli

  2. Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

    Maria Alessandra Calegari

  3. Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

    Maurizio Martini

  4. Surgery, Oncology, and Stomatology Unit, University of Palermo, Palermo, Italy

    Stefano Rotolo

Authors
  1. Andrea Di Giorgio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Santullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miriam Attalla El Halabieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudio Lodoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo Abatini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Alessandra Calegari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurizio Martini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stefano Rotolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fabio Pacelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FS, SR, AD, and FP contributed to study conception and design. CA, MAEH, and MAC contributed to acquisition of data. FS, MAEH, and SR contributed to writing the manuscript. MAEH, CL, and MM contributed to drafting of the manuscript. FS, AD, and FP contributed to critical revision. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Francesco Santullo.

Ethics declarations

Ethics approval

This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the local Institutional Review Board (IRB).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Giorgio, A., Santullo, F., Attalla El Halabieh, M. et al. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer. J Gastrointest Surg 25, 2649–2659 (2021). https://doi.org/10.1007/s11605-021-05073-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-021-05073-3

Keywords

Search

Navigation